Evaluation of epidermal growth factor receptor (EGFR) as a prognostic factor for survival in non-small-cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy as first-line treatment.

被引：0
|
作者：
Janas, M
Bailey, LR
Schmidt, K
Bindslev, N
Wolf, M
Fandi, A
Askaa, J
Herbst, R
Giaccone, G
Johnson, DH
机构：
[1] DakoCytomat AS, Glostrup, Denmark
[2] AstraZeneca, Wilmington, DE USA
[3] SpadilleMediMentum, Fredensborg, Denmark
[4] AstraZeneca Macclesfield, Macclesfield, Cheshire, England
[5] MD Anderson Canc Ctr, Houston, TX USA
[6] Free Univ Amsterdam, Sch Med, Amsterdam, Netherlands
[7] Vanderbilt Univ, Sch Med, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7024
引用
收藏
页码：622S / 622S
页数：1
相关论文
共 50 条
  • [1] Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy.
    Bailey, LR
    Janas, M
    Schmidt, K
    Bindslev, N
    Wolf, M
    Grous, J
    Askaa, J
    Herbst, R
    Johnson, DH
    Giaccone, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 620S - 620S
  • [2] Response to first-line chemotherapy and sensitivity to epidermal growth factor receptor (EGFR) inhibitors in advanced non-small-cell lung cancer (NSCLC) patients
    Betti, Maura
    Toschi, L.
    Metro, G.
    Bartolini, Stefania
    Magrini, E.
    de Angelis, Verena
    Chiari, Rita
    Ferraldeschi, Massimiliano
    Cappuzzo, Federico
    Crino, Lucio
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 235 - 235
  • [3] Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
    O'Leary, Connor
    Gasper, Harry
    Sahin, Katherine B.
    Tang, Ming
    Kulasinghe, Arutha
    Adams, Mark N.
    Richard, Derek J.
    O'Byrne, Ken J.
    [J]. PHARMACEUTICALS, 2020, 13 (10) : 1 - 16
  • [4] Epidermal growth factor receptor (EGFR) enhanced expression in chemoresistant non-small-cell lung carcinoma (NSCLC) after platinum-based therapy
    Val, D
    Majo, J
    Rojo, F
    Felip, F
    De Torres, I
    Baselga, J
    Cajal, SRY
    [J]. MODERN PATHOLOGY, 2005, 18 : 319A - 319A
  • [5] Epidermal growth factor receptor (EGFR) enhanced expression in chemoresistant non-small-cell lung carcinoma (NSCLC) after platinum-based therapy
    Val, D
    Majo, J
    Rojo, F
    Felip, E
    De Torres, I
    Baselga, J
    Ramon, S
    [J]. LABORATORY INVESTIGATION, 2005, 85 : 319A - 319A
  • [6] Erlotinib as first-line treatment of European non-small-cell lung cancer (NSCLC) patients (pts.) with epidermal growth factor receptor (EGFR) activating mutations (mut plus )
    Petruzelka, Lubos
    [J]. LUNG CANCER, 2012, 77 : S25 - S25
  • [7] Evaluation of weight gain and overall survival of patients with advanced non-small cell lung cancer (NSCLC) treated with first-line platinum-based chemotherapy.
    Roeland, Eric
    Fintelmann, Florian J.
    Hilton, Fiona
    Tarasenko, Lisa
    Calle, Roberto A.
    Bonomi, Philip D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [8] Thromboembolic events (TE) in patients with metastatic non small cell lung cancer (NSCLC) EGFR/ALK native treated with first-line platinum-based chemotherapy
    Castellon Rubio, V. E.
    Luque Caro, R.
    Gonzalez Flores, E.
    Canosa Ruiz, L.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 116 - 116
  • [9] Epidermal growth factor receptor (EGFR) inhibition on non-small-cell lung cancer treatment
    Kowalski, Dariusz M.
    Krzakowski, Maciej
    Janowicz-Zebrowska, Anna
    [J]. ONCOLOGY IN CLINICAL PRACTICE, 2011, 7 (04): : 177 - 182
  • [10] Epidermal growth factor receptor (EGFR) mutation testing and first-line treatment with gefitinib as a strategy in the treatment of patients with advanced non-small cell lung cancer (NSCLC).
    Lopes, G.
    Segel, J.
    Tan, D. S. W.
    Do, Y.
    Mok, T.
    Finkelstein, E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345